Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia.
about
Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinaseThe splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia.Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib.Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.Ibrutinib inhibits SDF1/CXCR4 mediated migration in AMLSynergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma.Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphomaBruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer.Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia.Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma.Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC CellsOptimized Near-IR Fluorescent Agents for in Vivo Imaging of Btk Expression.Clinical significance of in vivo cytarabine-induced gene expression signature in AML.Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemiaTargeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection.Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation.The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia.PI3Kδ and PI3Kγ isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironment.Breaking good: the inexorable rise of BTK inhibitors in the treatment of chronic lymphocytic leukaemia.Overcoming bortezomib resistance in multiple myeloma.Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies.Deregulated KLF4 Expression in Myeloid Leukemias Alters Cell Proliferation and Differentiation through MicroRNA and Gene Targets.Emerging therapeutic targets for the treatment of human acute myeloid leukemia (part 1) - gene transcription, cell cycle regulation, metabolism and intercellular communication.CD79B limits response of diffuse large B cell lymphoma to ibrutinib.Ibrutinib synergizes with poly(ADP-ribose) glycohydrolase inhibitors to induce cell death in AML cells via a BTK-independent mechanismIbrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML.Distinct and Overlapping Functions of TEC Kinase and BTK in B Cell Receptor Signaling.Single cell imaging of Bruton's tyrosine kinase using an irreversible inhibitor.Acute myeloid leukaemia.Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemia.Role and regulation of microRNAs targeting BTK in acute myelogenous leukemia.Bruton's tyrosine kinase and RAC1 promote cell survival in MLL-rearranged acute myeloid leukemia.Novel Indications for Bruton's Tyrosine Kinase Inhibitors, beyond Hematological Malignancies.Understanding life and death decisions in human leukaemias.
P2860
Q27026912-C10FA6EF-51B4-48BB-B4FB-1F1ECC4A77F8Q30395427-B83F8E41-EB7A-490B-ACBB-C5EEA614DBA7Q33774517-7880D69C-7829-48DF-A1BC-31BA9FDAF6A8Q33779805-A2409706-0420-4874-9976-A2622B62B16AQ34042250-2DE1C2EF-62E5-4B16-A768-81AD90C884C8Q34104112-15F35FD9-8D08-4709-80C3-846B99605F43Q35140097-46578793-0F49-41BF-B263-A215787EEA51Q35220644-6AC88C69-2E3D-40BB-B228-1BDC83555A01Q35650181-E390C882-59AF-4A8D-BFE6-F72F72ABD9D5Q35979385-C3F3226E-293D-4DA6-98EF-1D5CAD28B341Q36183770-72BEA866-9A88-48F0-8B75-7B3F1FC920C5Q36544565-83E8806E-BDF9-4D46-A3A3-CA368230CF48Q36635267-A90B7804-0FF4-49C3-B78C-5791EE2C325BQ36693136-A56FCA16-3F47-477D-8A4E-CBA587062DC4Q37180382-E4E47F3F-03B4-4277-B4D6-BD53D3483399Q37457673-A90ED332-4C43-48AE-9438-84A1D4B708A2Q37688439-61D3A865-A5BE-400A-86BF-35F39047B95EQ37706488-EF1FF483-FCF3-4868-859B-E4BAAC867E1FQ37737793-962958BD-EA29-4EFE-B2FD-A45BC5886267Q38205852-84BD6E55-ADB4-4DA8-9C4C-D7705CCD80CAQ38238610-30B932E0-0A9E-4430-97ED-EF18BAC28A8BQ38351184-04C82A19-0ABF-460B-8BAB-19A263CC0984Q38384041-53C6CDCF-8A01-4C77-810C-7DEC0133B4CFQ38401664-762E5B05-7A89-4DA7-8039-FA87DD60D297Q38809445-6A4EF9D7-9104-44D4-BF3F-3F142DC69C79Q38815360-42E98898-8E5A-4EC5-8AD2-B156E4B5EF99Q38857067-BBC3EE0C-DDC4-4D62-A6BC-F1D9D0A3B393Q38919666-37BFF878-518A-4987-984D-895C1F1889D5Q38938436-1F4B101E-D86C-492F-B69C-835F5B53CF69Q47432401-F4F01211-E4FA-4C06-A0F2-31B7F7AC29C2Q49950976-F1A29B97-5C34-4FB5-B1A2-4B86CBC0A61EQ50054874-F2E56212-A290-4F5C-9973-592CC3DF7033Q50131810-44CCF3F5-D73A-4118-87D8-B1B2526AA6A1Q52645038-D17BCF3F-C327-41CB-A93A-FC24856C3160Q55071953-734AA001-6DF7-44B1-AF02-B7605D882F62
P2860
Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Identification of Bruton's tyr ...... get in acute myeloid leukemia.
@en
Identification of Bruton's tyr ...... get in acute myeloid leukemia.
@nl
type
label
Identification of Bruton's tyr ...... get in acute myeloid leukemia.
@en
Identification of Bruton's tyr ...... get in acute myeloid leukemia.
@nl
prefLabel
Identification of Bruton's tyr ...... get in acute myeloid leukemia.
@en
Identification of Bruton's tyr ...... get in acute myeloid leukemia.
@nl
P50
P1433
P1476
Identification of Bruton's tyr ...... get in acute myeloid leukemia.
@en
P2093
Lyubov Zaitseva
Megan Y Murray
P304
P356
10.1182/BLOOD-2013-06-511154
P407
P577
2013-12-04T00:00:00Z